Skip to main content

HCANYS, Hospice Members Convene with Nationals, State Medical Society & DOH in High-Level Meeting Discussion of Proposed Federal DEA Prescribing Rule

The Situation Report | March 10, 2025

Addressing serious concerns with a January Biden Administration proposal restricting elements of telehealth prescribing of controlled substances, HCANYS and HCANYS hospice members convened in a high-level, high-stakes special meeting last week to provide critical input for national advocacy responding to this proposal.

The HCANYS meeting included HCPANYS program staff, hospice providers, medical directors, legal experts from our national affiliate the National Alliance for Care at Home (formerly the National Association for Home Care & Hospice and the National Hospice & Palliative Care Association), representatives from the Medical Society of the State of New York (MSSNY), and officials from the NYS Department of Health.

The Alliance's review of the proposal can be viewed here.

The proposal, issued by the Federal Drug Enforcement Administration (DEA), carries particular ramifications for hospice patients and providers. While intended to provide safety measures for prescribing and potential illicit access to controlled substances as a matter of national drug enforcement, the proposal appears duly uninformed from a health care and, in particular, a hospice perspective.

There is wide concern across HCANYS, our hospice membership and nationally that the rule would impose serious impactful registration requirements; patient in-person encounter requirements; time delays; and other conflicts with basic, essential practices for timely prescribing of controlled medications for hospice patients. Physicians participating in the HCANYS meeting expressed their deepest concerns for the potential catastrophic effects of the rule on hospice access, pain relief, access, and even the viability of community based hospice services.

As HCANYS is currently following up with our hospice membership, the participating physicians, and other meeting participants to garner further input preparatory to drafting of federal advocacy materials to provide to the DEA, HCANYS hospice members, their medical directors, and home health representatives are encouraged to submit additional comments and input for the advocacy process.  A recording to the meeting can be found here;  further input can be sent directly to This email address is being protected from spambots. You need JavaScript enabled to view it. under the subject line “Federal DEA Proposal for Telehealth Prescribing.”  For further information or comment, please contact HCANYS President Al Cardillo at This email address is being protected from spambots. You need JavaScript enabled to view it., who participates directly in the national discussions of the Alliance on this issue.

HCANYS thanks our hospice members for the impassioned and expert input on this issue; our colleagues at the Alliance, especially Patrick Harrison, JD., Senior Director, Regulatory & Compliance, who co-led the discussion with HCANYS; Katie Wehri, Vice President, Regulatory Affairs, Quality & Compliance for her leadership and advocacy; and colleagues from MSSNY and DOH for this critical collaboration.